Company Overview and News
2018-09-28 reuters - 1
NEW YORK, Sept 28 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 131.48 points, or 0.81 percent, to 16,073.14. * Leading the index were BlackBerry Ltd, up 10.2 percent, Paramount Resources Ltd, up 7.6 percent, and Aurora Cannabis Inc, higher by 6.3 percent. * Lagging shares were West Fraser Timber Co Ltd, down 6.4 percent, Norbord Inc, down 4.9 percent, and First Quantum Minerals Ltd, lower by 4.
TRQ ACB ACBFF FQVLF NBRXF TRQ FQM POU OSB BBRY PRMRF
NEW YORK, Sept 24 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 16.81 points, or 0.10 percent, to 16,207.32. * Leading the index were Baytex Energy Corp, up 10.7 percent, Gran Tierra Energy Inc, up 8.3 percent, and Paramount Resources Ltd , higher by 6.8 percent. * Lagging shares were New Gold Inc, down 16.3 percent, First Quantum Minerals Ltd, down 7.1 percent, and Maxar Technologies Ltd, lower by 5.
NGD ABX ACBFF NGDAF NGD ACB FQVLF GTE BTE FQM POU MAXR GTE PRMRF ABX
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES
KEL CPS KELTF POU CLMPF PRMRF
July 30 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 48.48 points, or 0.30 percent, to 16,345.47. * The biggest percentage decliners were Shopify Inc, down 8.4 percent, Canada Goose Holdings Inc, down 6.6 percent, and Kinaxis Inc, lower by 5.9 percent. * Leading percentage gainers were Ivanhoe Mines Ltd, up 4.9 percent, Air Canada, up 3.8 percent, and Paramount Resources Ltd , higher by 3.
GOOS CVE ACBFF IVN AC SHOP IVPAF MFC ACB 0945 ACDVF CVE MFC POU PRMRF
NEW YORK, June 15 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 14.54 points, or 0.09 percent, to 16,314.42 but climbed 0.69 percent on the week, its second straight weekly gain. * The biggest contributor to the TSX loss was Toronto-Dominion Bank, pulling 7.6 points from the index. Energy was the heaviest sector drag, with 32.3 net points. * Leading the index were Canada Goose Holdings Inc, up 30 percent in the wake of its quarterly results, Paramount Resources Ltd, up 4 percent, and Prometic Life Sciences Inc, higher by 3.
FR CVE GOOS TNTTF PDS TD TECK CVE BDRPF AG TCKRF POU PFSCF TD PRMRF
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ECN SIA SIA.DB SLF CMDXF TXCX ECA SLF ECA CMG AEM SLFYF POU PRMRF SLF
NEW YORK, May 10 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 48.69 points, or 0.31 percent, to 15,959.50. * The biggest contributor to the TSX gain was Enbridge, up 1.9 percent, to add 9.45 net index points after the pipeline company posted quarterly results and said it may sell more assets this year. Materials was the top sector contributor with a 15 net points boost.
ENBBF OTEX PAAS ENB GCGMF ENB GC OTC CNQ TSG EBBNF BTE CADNF POU PRMRF
Prospects are looking brighter in the Canadian oilpatch as commodity price increases drive higher profits and afford companies room to offer dividend hikes and share buybacks — but slumping stock prices show that the oil and gas sector remains in the penalty box with investors.
CVE BIR BIREF HUSKF SU TOU HSE KMI CNQ CVE TRMLF KMR POU CVB KMRFZ PRMRF SU
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:POU / Paramount Resources Ltd. on message board site Silicon Investor.